Asia Pacific Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023

List of Tables

The Asia Pacific Oncology Drugs Market would witness market growth of 8.5% CAGR during the forecast period (2023-2030).

The advent of molecular biology and genomic sequencing technologies has unraveled the intricate genetic mutations and alterations that drive cancer progression. This deeper understanding of the molecular landscape of various cancers has paved the way for developing targeted therapies designed to specifically inhibit or modulate the aberrant pathways responsible for tumor growth. Immunotherapy has emerged as a game-changer in the market. Immunotherapeutic agents have demonstrated remarkable success in treating certain cancers by harnessing the body's immune system to identify and eliminate cancer cells. Checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines are innovative immunotherapies that have shown promise in improving patient outcomes.

The era of personalized drugs has arrived, and the market is at the forefront of this paradigm shift. Biomarker discovery, driven by advances in omics technologies, allows for identifying specific genetic, epigenetic, or proteomic signatures associated with different cancer types. This information enables the development of drugs tailored to individual patients, optimizing treatment efficacy, and minimizing side effects. Pharmaceutical companies and research institutions invest heavily in oncology research and drug development. The competitive landscape is characterized by many players striving to bring novel therapies to market. These investments drive innovation and contribute to expanding the market, offering patients a more comprehensive array of treatment options.

The Asia Pacific region has grown substantially in its biotechnology and pharmaceutical industries. Increased investment in research and development by domestic and multinational companies has fueled the development and commercialization of these drugs. The implementation of precision medicine in breast cancer treatment involves tailoring therapies based on the specific genetic and molecular characteristics of individual tumors. Genomic testing allows oncologists to identify targetable mutations, guiding the selection of personalized drugs. The factors mentioned above will propel the market growth in this region.

The China region dominated the Asia Pacific Oncology Drugs Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $19,020 million by 2030. The Japan region is registering a CAGR of 7.9% during (2023 - 2030). Additionally, The India region would showcase a CAGR of 9.2% during (2023 - 2030).

Based on Indication, the market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancer. Based on Drug Class Type, the market is segmented into Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.

Scope of the Study

Market Segments covered in the Report:

By Indication

Breast Cancer
Prostate Cancer
Lung Cancer
Stomach Cancer
Colorectal Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancer

By Drug Class Type

Targeted Therapy
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy

By Country

China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific

Companies Profiled

AbbVie, Inc.
Amgen, Inc.
Astellas Pharma, Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
Pfizer Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Asia Pacific Oncology Drugs Market, by Indication
- 1.4.2 Asia Pacific Oncology Drugs Market, by Drug Class Type
- 1.4.3 Asia Pacific Oncology Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global

4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
- 4.2.1 Partnerships, Collaborations and Agreements
- 4.2.2 Product Launches and Product Expansions
- 4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
- 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar - 2023, Nov) Leading Players
4.4 Porter's Five Forces Analysis

Chapter 5. Asia Pacific Oncology Drugs Market by Indication

5.1 Asia Pacific Breast Cancer Market by Country
5.2 Asia Pacific Prostate Cancer Market by Country
5.3 Asia Pacific Lung Cancer Market by Country
5.4 Asia Pacific Stomach Cancer Market by Country
5.5 Asia Pacific Colorectal Cancer Market by Country
5.6 Asia Pacific Liver Cancer Market by Country
5.7 Asia Pacific Esophagus Cancer Market by Country
5.8 Asia Pacific Cervical Cancer Market by Country
5.9 Asia Pacific Kidney Cancer Market by Country
5.10. Asia Pacific Bladder Cancer Market by Country
5.11 Asia Pacific Other Cancer Market by Country

Chapter 6. Asia Pacific Oncology Drugs Market by Drug Class Type

6.1 Asia Pacific Targeted Therapy Market by Country
6.2 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country
6.3 Asia Pacific Chemotherapy Market by Country
6.4 Asia Pacific Hormonal Therapy Market by Country

Chapter 7. Asia Pacific Oncology Drugs Market by Country

7.1 China Oncology Drugs Market
- 7.1.1 China Oncology Drugs Market by Indication
- 7.1.2 China Oncology Drugs Market by Drug Class Type
7.2 Japan Oncology Drugs Market
- 7.2.1 Japan Oncology Drugs Market by Indication
- 7.2.2 Japan Oncology Drugs Market by Drug Class Type
7.3 India Oncology Drugs Market
- 7.3.1 India Oncology Drugs Market by Indication
- 7.3.2 India Oncology Drugs Market by Drug Class Type
7.4 South Korea Oncology Drugs Market
- 7.4.1 South Korea Oncology Drugs Market by Indication
- 7.4.2 South Korea Oncology Drugs Market by Drug Class Type
7.5 Singapore Oncology Drugs Market
- 7.5.1 Singapore Oncology Drugs Market by Indication
- 7.5.2 Singapore Oncology Drugs Market by Drug Class Type
7.6 Malaysia Oncology Drugs Market
- 7.6.1 Malaysia Oncology Drugs Market by Indication
- 7.6.2 Malaysia Oncology Drugs Market by Drug Class Type
7.7 Rest of Asia Pacific Oncology Drugs Market
- 7.7.1 Rest of Asia Pacific Oncology Drugs Market by Indication
- 7.7.2 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type

Chapter 8. Company Profiles

8.1 AbbVie, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
  - 8.1.5.1 Partnerships, Collaborations, and Agreements:
  - 8.1.5.2 Acquisition and Mergers:
- 8.1.6 SWOT Analysis
8.2 Amgen, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
  - 8.2.5.1 Acquisition and Mergers:
- 8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
  - 8.3.5.2 Acquisition and Mergers:
- 8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Partnerships, Collaborations, and Agreements:
  - 8.4.5.2 Product Launches and Product Expansions:
- 8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Partnerships, Collaborations, and Agreements:
  - 8.5.5.2 Product Launches and Product Expansions:
  - 8.5.5.3 Acquisition and Mergers:
- 8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
  - 8.6.5.1 Partnerships, Collaborations, and Agreements:
  - 8.6.5.2 Product Launches and Product Expansions:
  - 8.6.5.3 Acquisition and Mergers:
- 8.6.6 SWOT Analysis
8.7 Johnson & Johnson
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental & Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Partnerships, Collaborations, and Agreements:
  - 8.7.5.2 Acquisition and Mergers:
- 8.7.6 SWOT Analysis
8.8 Novartis AG
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Partnerships, Collaborations, and Agreements:
- 8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 Recent strategies and developments:
  - 8.9.5.1 Partnerships, Collaborations, and Agreements:
  - 8.9.5.2 Acquisition and Mergers:
- 8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional & Segmental Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 Recent strategies and developments:
  - 8.10.5.1 Partnerships, Collaborations, and Agreements:
- 8.10.6 SWOT Analysis

LIST OF TABLES

TABLE 1 Asia Pacific Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Oncology Drugs Market
TABLE 4 Product Launches And Product Expansions- Oncology Drugs Market
TABLE 5 Acquisition and Mergers- Oncology Drugs Market
TABLE 6 Asia Pacific Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 7 Asia Pacific Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 8 Asia Pacific Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 Asia Pacific Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 Asia Pacific Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 11 Asia Pacific Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 12 Asia Pacific Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 13 Asia Pacific Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 14 Asia Pacific Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 15 Asia Pacific Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 16 Asia Pacific Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 17 Asia Pacific Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 18 Asia Pacific Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 19 Asia Pacific Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 20 Asia Pacific Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 21 Asia Pacific Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 22 Asia Pacific Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 23 Asia Pacific Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 24 Asia Pacific Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 25 Asia Pacific Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 26 Asia Pacific Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 27 Asia Pacific Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 28 Asia Pacific Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 29 Asia Pacific Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 30 Asia Pacific Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 31 Asia Pacific Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 32 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 33 Asia Pacific Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 34 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 35 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 36 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 37 Asia Pacific Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 38 Asia Pacific Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 Asia Pacific Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 Asia Pacific Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 41 Asia Pacific Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 42 China Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 43 China Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 44 China Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 45 China Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 46 China Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 47 China Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 48 Japan Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 49 Japan Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 50 Japan Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 51 Japan Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 52 Japan Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 53 Japan Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 54 India Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 55 India Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 56 India Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 57 India Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 58 India Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 59 India Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 60 South Korea Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 61 South Korea Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 62 South Korea Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 63 South Korea Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 64 South Korea Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 65 South Korea Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 66 Singapore Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 67 Singapore Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 68 Singapore Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 69 Singapore Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 70 Singapore Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 71 Singapore Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 72 Malaysia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 73 Malaysia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 74 Malaysia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 75 Malaysia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 76 Malaysia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 77 Malaysia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 78 Rest of Asia Pacific Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 79 Rest of Asia Pacific Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 80 Rest of Asia Pacific Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 81 Rest of Asia Pacific Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 82 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 83 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 84 Key information - AbbVie, Inc.
TABLE 85 Key Information - Amgen, Inc.
TABLE 86 key information - Astellas Pharma, Inc.
TABLE 87 KEY INFORMATION - AstraZeneca PLC
TABLE 88 Key Information - Bristol Myers Squibb Company
TABLE 89 Key Information - F. Hoffmann-La Roche Ltd.
TABLE 90 Key Information - Johnson & Johnson
TABLE 91 Key Information - Novartis AG
TABLE 92 Key Information - Merck & Co., Inc.
TABLE 93 Key Information - Pfizer, Inc.

Asia Pacific Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents